Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
复制标题
DOI：
10.1016/j.cllc.2014.06.002
复制
发表时间：
2014-11-01
影响因子：
3.6
通讯作者：
Azzoli, Christopher G.
中科院分区：
文献类型：
--
作者：
Chaft, Jamie E.;Litvak, Anya;Azzoli, Christopher G.
这项II期研究评价了GI-4000（一种表达突变型KRAS（Kirsten大鼠肉瘤病毒致癌基因同源物）蛋白的酵母衍生疫苗）在完成治愈性治疗的早期KRAS突变型肺癌患者中的可行性、免疫原性和安全性。24名患者接受了基因型匹配的GI-4000疫苗，
This phase II study evaluated the feasibility, immunogenicity, and safety of GI-4000, a yeast derived vaccine expressing mutant KRAS (Kirsten rat sarcoma viral oncogene homolog) proteins, in patients with early stage KRAS mutant lung cancers who completed curative therapy. Twenty-four patients received the genotype matched GI-4000 vaccine for